Fiera Capital Corp Trims Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Fiera Capital Corp decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 137,588 shares of the company’s stock after selling 3,610 shares during the quarter. Fiera Capital Corp’s holdings in IDEXX Laboratories were worth $57,780,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its position in IDEXX Laboratories by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company’s stock valued at $948,279,000 after purchasing an additional 37,734 shares during the period. Bamco Inc. NY raised its position in IDEXX Laboratories by 4.3% in the fourth quarter. Bamco Inc. NY now owns 2,005,522 shares of the company’s stock valued at $829,163,000 after purchasing an additional 82,264 shares during the period. Invesco Ltd. raised its position in IDEXX Laboratories by 6.8% in the fourth quarter. Invesco Ltd. now owns 1,160,988 shares of the company’s stock valued at $479,999,000 after purchasing an additional 74,324 shares during the period. Principal Financial Group Inc. raised its position in IDEXX Laboratories by 58.3% in the first quarter. Principal Financial Group Inc. now owns 1,126,002 shares of the company’s stock valued at $472,865,000 after purchasing an additional 414,802 shares during the period. Finally, GAMMA Investing LLC raised its position in IDEXX Laboratories by 59,810.7% in the first quarter. GAMMA Investing LLC now owns 918,431 shares of the company’s stock valued at $3,856,950,000 after purchasing an additional 916,898 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Up 0.2%

IDEXX Laboratories stock opened at $566.50 on Tuesday. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $570.36. The stock’s fifty day simple moving average is $527.49 and its 200-day simple moving average is $468.45. The company has a current ratio of 1.16, a quick ratio of 0.81 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $45.56 billion, a P/E ratio of 52.36, a P/E/G ratio of 4.11 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping analysts’ consensus estimates of $2.93 by $0.03. The firm had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. The company’s revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.71 earnings per share. As a group, equities analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analyst Ratings Changes

IDXX has been the topic of a number of research analyst reports. Stifel Nicolaus boosted their target price on IDEXX Laboratories from $510.00 to $540.00 and gave the company a “hold” rating in a research report on Wednesday, July 2nd. Jefferies Financial Group assumed coverage on IDEXX Laboratories in a research report on Tuesday, July 1st. They set a “buy” rating and a $625.00 price objective on the stock. Morgan Stanley upped their price objective on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an “overweight” rating in a research report on Monday, May 5th. Wall Street Zen raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, July 12th. Finally, Leerink Partners upped their price objective on IDEXX Laboratories from $580.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, July 17th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $557.88.

Insider Activity at IDEXX Laboratories

In related news, Director M Anne Szostak sold 1,260 shares of the business’s stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total transaction of $645,548.40. Following the completion of the transaction, the director owned 1,801 shares in the company, valued at approximately $922,724.34. The trade was a 41.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.